The
2021 Metrics of the HUPO Human Proteome Project (HPP) show
that protein expression has now been credibly detected (neXtProt PE1
level) for 18 357 (92.8%) of the 19 778 predicted proteins
coded in the human genome, a gain of 483 since 2020 from reports throughout
the world reanalyzed by the HPP. Conversely, the number of neXtProt
PE2, PE3, and PE4 missing proteins has been reduced by 478 to 1421.
This represents remarkable progress on the proteome parts list. The
utilization of proteomics in a broad array of biological and clinical
studies likewise continues to expand with many important findings
and effective integration with other omics platforms. We present highlights
from the Immunopeptidomics, Glycoproteomics, Infectious Disease, Cardiovascular,
Musculo-Skeletal, Liver, and Cancers B/D-HPP teams and from the Knowledgebase,
Mass Spectrometry, Antibody Profiling, and Pathology resource pillars,
as well as ethical considerations important to the clinical utilization
of proteomics and protein biomarkers.